• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

Insomnia costs U.S. workers $63B a year – Here are 4 Companies Developing Treatments

October 12, 2011 by admin

According to a recent study, insomnia costs the average US worker 11.3 days in productivity (about $2,280) every year, amounting to $63 billion annually. This impact is much greater than the researchers had expected.

“It’s an underappreciated problem. Americans are not missing work because of insomnia. They are still going to their jobs, but accomplishing less because they’re tired. In an information-based economy, it’s difficult to find a condition that has a greater effect on productivity,” says Ronald Kessler, professor of healthcare policy at Harvard Medical School, who led the study.

The sample of 7,428 employees was taken nationally. Among them, 23.2% were estimated to have insomnia. It was more common in workers under 65 years old, and more common in women than men.

The more that insomnia is recognized as a serious problem in labor productivity, the more U.S. employers will be obliged to address the issue.

For a look at companies that may stand to benefit, we’ve listed 4 biotech companies that are developing treatments.

1. Alexza Pharmaceuticals Inc. (ALXA): Focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Market cap of $88.73M. The company’s clinical-stage product candidates include AZ-007 (staccato zaleplon), which completed Phase I status for the treatment of insomnia.

2. Neurocrine Biosciences Inc. (NBIX): Engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Market cap of $313.21M. The company develops drugs for insomnia and other neurological disorders

3. Questcor Pharmaceuticals, Inc. (QCOR): Provides prescription drugs for central nervous system and inflammatory disorders. Market cap of $2.05B. The company markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

4. SciClone Pharmaceuticals, Inc. (SCLN): Engages in the development and commercialization of novel therapeutics for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in the People’s Republic of China and internationally. Market cap of $230.95M. Its products include Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance.

Source: Nasdaq Community – For more information

Filed Under: Blog

Primary Sidebar

More to See

Snoring, American Sleep and Breathing Academy and the NY Times

August 23, 2022 By admin

Jazz Pharma Presents 17 New Posters for SLEEP 2022

June 6, 2022 By admin

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep heart health sleep industry sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • SUPPORT AND PROMOTE DENTAL SLEEP MEDICINE IN 2023!
  • Snoring, American Sleep and Breathing Academy and the NY Times
  • Jazz Pharma Presents 17 New Posters for SLEEP 2022
  • AJMC Hypes SLEEP 2022
  • Avadel Pharmaceuticals’ Stock Falls

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2023 · Sleep Diagnosis and Therapy